CNSY
Plus Therapeutics, Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$1.65
−2.94%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +103.4%
- EBITDA
- +25.8%
- EPS
- +99.7%
Three-year CAGR
- Revenue
- +185.5%
- EBITDA
- —
- EBIT
- -4.1%
- Net income
- -72.5%
- EPS
- +85.3%
- Free cash flow
- -94.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026